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Abstract
Background:  Human  immunodeficiency  virus/acquired  immunodeficiency  syndrome  (HIV/AIDS)  is  a major public 
health problem in sub-saharan Africa. Cytomegalovirus (CMV) has been reported to enhance HIV replication and accelerate 
the progression of  HIV infection to AIDS.
Objective: This study reports on the high seropositivity of  immunoglobulin (Ig) G and M antibodies against CMV and the 
risk factors for CMV infection among HIV/AIDS patients in Ilorin, Nigeria.
Method: A total of  180 consented HIV-1 seropositive patients (age-range 16-56 years; 108 females and 72 males) were con-
secutively recruited. Socio-demographic/behavioral data and 5 ml blood samples were collected from each patient. Plasma 
of  each sample was assayed for anti-CMV IgG/IgM using a CMV IgG and IgM Enzyme Linked ImmunoSorbent Assay 
(ELISA) kit.
Results: Twenty (11.1%) of  the 180 HIV-1 seropositive subjects were positive for anti-CMV IgM antibody while 169(93.9%) 
were positive for anti-CMV IgG antibody. Age, marital status, number of  sexual partners, CD4 cells counts and previous 
history of  blood transfusion were the main correlates of  CMV seropositivity among these patients. However, occupation, 
sex, highly active antiretroviral therapy (HAART) were not statistically associated with CMV seropositivity in this study.
Conclusion: This study has shown that greater percentages of  HIV-1 seropositive patients had active CMV infection. It has 
further shown that CMV is hyperendemic in HIV-1 seropositive patients in Ilorin, Nigeria.
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Human cytomegalovirus (HCMV) is a ubiquitous agent 
that can cause infection at any time during the course 
of  life and commonly infects individuals from diverse 
geographical and socio-economic backgrounds1-2. By 
serology, 30% to 100% of  the general population ex-
hibit prior exposure to the virus3. The virus often caus-
es asymptomatic infection in healthy persons; when 
symptomatic, HCMV infection presents with three 
recognizable clinical syndromes4.
HCMV is also a virus most frequently transmitted to 
developing foetus, causing birth defects in new born 
and immune defect in later life and increase morbidity 
and mortality5. About 2.0% of  pregnant women have 
either a primary or a restricted HCMV infection during 
pregnancy and it is estimated that 10-20% of  congeni-
tally infected newborns show evidence of  the infection 
6.
Infections by HCMV continue to be an important 
health problem in certain patient populations, such as 
newborns, recipients of  solid organs or bone marrow 
and AIDS patients. In these groups, HCMV is a major 
cause of  morbidity and mortality. In various parts of  
the world, the prevalence of  HCMV ranges from 40-
100%2. The risk of  exposure to HCMV increases with 
age7. As with other herpes viruses, HCMV remains la-
tent in the infected host throughout life and rarely re-
activates to cause clinical illness except in immunocom-
promised individuals7-9.
HCMV infection is more prevalent in populations at 
African Health Sciences Vol 15 Issue 1, March 20151
risk for HIV infection; approximately 75% of  injec-
tion drug users and >90% of  homosexual men who 
are infected with HIV have detectable IgG antibodies 
to CMV [10]. HCMV infection is nearly ubiquitous in 
HIV-infected subjects and may lead to CMV end-organ 
disease (EOD) and death as a consequence of  the im-
paired immunity2,7,10.
Prior to the introduction of  combination antiretroviral 
therapy, HCMV EOD was common in advanced HIV 
infection, typically occurring with CD4 cell count of  
<100 cells/mm37,10-11. The detection of  virus- specific 
IgG and IgM antibodies is of  great value in the diagno-
sis of  acute/primary virus infections or reactivation of  
a latent one, in the absence of  typical clinical symptoms.
This study aims to determine the prevalence of  an-
ti-HCMV IgG and IgM antibodies in HIV positive 
patients with and without past history of  blood trans-
fusion. The findings from this work may help to devel-
op policy whether CMV screening should be routinely 
done before transfusing HIV infected patients, or in a 
case of  high seroprevalence of  CMV amongst the gen-
eral population, the use of  leukoreduced blood units for 
anaemic HIV infected patients, may be recommended, 
since CMV is transmitted through the white blood cell.
Methods 
Study area
This prospective study was carried out at the University 
of  Ilorin Teaching Hospital (UITH) Ilorin. The
teaching hospital provides healthcare services to the 
people of  Kwara and neighboring States. UITH in 
conjunction with the Institute of  Human Virology of  
Nigeria (IHVN) provides free health care services to 
people living with HIV/AIDS in Ilorin and its environ-
ment.
Ethical consideraton
A written consent was obtained from participants after 
carefully explaining the concept of  the study to them.
Ethical clearance was sought and obtained from the 
ethical and research committee of  the University of  Il-
orin Teaching Hospital, Ilorin, Nigeria.
Experimental design
A total of  180 consented HIV seropositive patients at-
tending the HAART clinic of  UITH, Ilorin were re-
cruited  for  this  study.  The  demographic  data  of   the 
participants  were  entered  into  a  structured question-
naire designed for the study. A serological survey was 
done by collecting blood samples from all participants 
for HCMV IgG and IgM. These samples were sent in 
Giostyle box with ice packs to preserve the cold chain 
to the laboratory. Serum was extracted from each sam-
ple by centrifugation at 3000 rpm for 5 minutes using 
ES5 centrifuge. All the sera obtained were stored frozen 
at -200C until analysis was done.
Blood collection and serological analysis
Five milliliters of  blood was collected into sterile antico-
agulant-free bottle. Each sample was centrifuged after 
the blood had clotted and serum separated into sterile 
bottles on each collection day for storage at -20OC. All 
specimens were screened for HCMV specific–IgM and 
IgG antibodies using IgM and IgG ELISA Kit man-
ufactured by DIA.PRO Diagnostic Bioprobes Srl Via 
Columella nO31 20128 Milano – Italy. The testswere 
done according to manufacturer’s instructions. The cut-
off  of  the device was set at 0.5 WHO IU/ml (Calibera-
tor 2) by the kit’s manufacturer. Samples with a concen-
tration higher than 0.5 WHO IU/ml were considered 
positive for CMV IgG whilst samples with concentra-
tion below the cut-off  were regarded as negative results. 
All reactive samples were repeated in duplicate for IgM 
tests and accepted as positive. 
 
Sensitivity and specificity of  the Elisa kits
The value, obtained from the analysis of  more than 300 
specimens, has been > 98% of  sensitivity. An overall 
value > 98% of  specificity was found when examined 
on more than 100 specimens.
Data analysis
Data was analyzed using Microsoft Excel 2007 version 
to calculate the International Unit (IU) from Optical 
Density (OD).  Values below 0.5 were considered nega-
tive and values above 0.5 were considered positive. Sta-
tistical Package for Social Sciences (SPSS, version 19.0) 
software was used to calculate descriptive statistics.
Results
Patients’ characteristics
Of  a total of  180 consented HIV-1 seropositive patients 
that participated in the study, 108 (60.0%) were females 
while males were 72 (40.0%) in number giving a male to 
female ratio of  1:1.3. Socio-demographic data of  HIV-
1 seropositive patients tested for anti-CMV IgG/IgM 
antibodies are shown in Table 1 and 2. Behavioral data 
of  HIV-1 patients tested for anti-CMV IgG/IgM anti-
bodies are shown in Table 3 and 4.
Distribution of  anti-HCMV IgM antibody among 
HIV-1 seropositive subjects
Twenty (11.1%) of  the 180 HIV-1 seropositive subjects 
were positive for anti-CMV IgM antibody while
169(88.9%) were positive for anti-CMV IgG antibody 
(Table 1).
Table 1 shows the socio-demographic data and sero-
positive outcome of  HIV-1 seropositive patients tested 
Table 1: Socio-demographic data and seropositive outcome of HIV-1 patients tested for anti-CMV 
     IgG/IgM antibodies       
Variables        No. No.       Positive Statistical No. Positive (%)     Statistical Values
Tested   (%)                         Values                    
for anti-CMV IgG/IgM antibodies. The study shows 
significant difference in anti-CMV IgG and anti-CMV 
IgM antibodies among the various age groups tested 
(X2= 1.454, p-value=0.000) (Table 1). It showed that 
the prevalence of  anti-CMV IgM was higher in age 
groups 16-25 years (14.3%), followed by age groups 26-
35 years (13.5%), 36-45 years (9.9%) and age group 46 
years and above had the least prevalence (5.6%). In the 
same vein, the prevalence of  anti-CMV IgG was higher 
in age groups 16-25 years (100.0%) and age group 46 
years and above (100.0%), followed by age groups 26-
35 years (95.9%) and 36-45 years (90.1%) as shown in 
Table 1.
There was no significant difference (X2= 1.784 p-val-
ue=0.629) in the seropositivity outcome of  anti-CMV 
IgM antibody among the two sex groups. The preva-
lence of  anti-CMV IgM was higher in males (13.9%) 
than their female counterparts (9.3%). In the same vein, 
the prevalence of  anti-CMV IgG was also higher in 
males (95.8%) than females (92.6%) as shown in Table 
1. Also from Table 1, it can be observed that there was 
no significant difference (X2 = 1.434, p-value =0.591) 
in the seropositivity outcome of  anti-CMV IgG anti-
bodies among the subjects (Table 1). The level of  an-
ti-CMV IgM and IgG antibodies seropositivity among 
the various marital groups was also statistically signifi-
cant (X2 = 1.306, p-value=0.002) (Table 1). The prev-
alence of  anti-CMV IgM was higher in singles (12.8%) 
than their married counterparts (11.0%) and others 
(7.1%). In the same vein, the prevalence of  anti-CMV 
IgG was also higher in singles (97.4%) than their mar-
ried counterparts (92.9%) and others (92.7%) as shown 
in Table 1.
The study shows no statistical association in the sero-
positivity outcome of  anti-CMV IgM antibody among 
the various occupational groups (Table 1). Also from 
Table 1, it can be observed that there was no significant 
difference (X2 = 1.434, p-value =0.591) in the seropos-
itivity outcome of  anti-CMV IgG antibodies among the 
subjects (Table 1). The prevalence of  anti-CMV IgM 
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                           (%)              Anti-CMV IgM                                    Anti-CMV IgG         
 
Age (years)  
16-25 7(3.9)  1(14.3)   7(100.0) 
26-35 74(41.1)  10(13.5)   71(95.9) 
36-45 81(45.0)  8(9.9)   73(90.1) 
 46 and above      18(10.0)            1(5.6)                         P<0.05                    18(100.0)                         P<0.05   
Sex 
Females            108(60.0)      10(9.3)                                                   100 (92.6) 
 Males                  72(40.0)            10(13.9)                         P>0.05                        69 (95.8)                         P>0.05   
 
Marital Status  
 
 
Single 39(21.7)  5(12.8)  38(97.4) 
Married 127(70.5)  14(11.0)  118(92.9) 
        Others                14(7.8)         1(7.1)                            P<0.05                    13(92.7)                       P<0.05   
 
Occupation  
Civil servants 20(11.1)  1(5.0)   16(80.0) 
Traders 100(55.6)  16(16.0)   100(100.0) 
Farmers 10(5.5)  1(10.0)   10(100.0) 
Others 30(16.7)  1(3.3)   27(90.0) 
 Unemployed             20(11.1)           1(5.0)                              P>0.05                     16(80.0)                           P>0.05   
Total               180(100.0)    20(11.1)                                                 169(93.9) 
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was higher among traders (16.0%), followed by farmers 
(10.0%), civil servants (5.0%) and unemployed subjects 
(5.0%) while other occupations had the least preva-
lence of  anti-CMV IgM (3.3%). In the same vein, the 
prevalence of  anti-CMV IgG was higher among trad-
ers (100.0%) and farmers (100.0%), followed by other 
occupations (90.0%), civil servants (80.0%) and unem-
ployed subjects (80.0%) as shown in Table 1. 
 
Behavioral data and seropositivity outcomes of  
HIV-1 seropositive patients tested for anti-CMV 
IgG/IgM antibodies
Table 2 shows the behavioral data and seropositivity 
outcomes of  HIV-1 seropositive patients tested for 
anti-CMV IgG/IgM antibodies. Our study also found 
significant difference (X2=24.25, p-value =0.000) in 
the seropositivity of  anti-CMV IgM and IgG antibodies 
among those with single (8.5% for IgM and 86.4% for 
IgG) and multiple sexual partners (12.4% for IgM and 
97.5% for IgG) as shown in Table 2. The study shows 
no significant difference (X2= 0.080, p-value=0.777) in 
the level of  anti-CMV IgM and anti-CMV IgG antibod-
ies among the HIV-1 seropositive patients on HAART 
(Table 2). The prevalence of  anti-CMV IgM was higher 
among subjects who were not on HAART (54.4%) than 
those on HAART (45.0%). In the same vein, the preva-
lence of  anti-CMV IgG was higher among subjects who 
were not on HAART (94.4%) than those on HAART 
(90.0%) as shown in Table 2. The results showed that of  
the 40 (22.2%) subjects with previous history of  blood 
transfusion; 6(15.0%) were seropositive for anti-CMV 
IgM and 38(90.0%) for anti- CMV IgG antibody. While 
among those with no history, 14(10.0%) were positive 
for anti-CMV IgM and 131(93.6%) for anti-CMV IgG 
antibody. There was significant difference (X2= 1.412, 
p-value=0.000) in the level of  anti-CMV IgM and an-
ti-CMV IgG antibodies among the two groups (Table 
2). The CD4 cell counts ranged from 17 - 321 cells/
mm3. There was significant association (X2= 1.155, 
p-value=0.0000) between CD4 cells count and seropos-
itivity outcome of  HIV-1 seropositive patients tested 
for anti-CMV IgM and anti-CMV IgG antibodies (Ta-
ble 2). 
Table  2:  Behavioral  data  and  seropositivity  outcomes  of  HIV-1  patients  tested  for  anti-CMV 
  IgG/IgM antibodies                  
Variables            No.   Tested 
(%) 
No.       Positive 
  (%)   
Statistical 
Values 
No.       Positive 





                           anti-CMV IgM                                  anti-CMV IgG      
Discussion
Cytomegalovirus (CMV) is a very frequent infection 
complicating AIDS. Sexual transmission appears to be 
the most common route of  infection in adults, though 
CMV can also be spread through oropharyngeal sec-
tions, urine, breast milk, and blood12-13. CMV-specific 
antibody of  the IgM class is a marker of  active or re-
cent primary infection with the virus. Post-transfusion 
CMV infection correlates positively with the receipt of  
blood from CMV IgM-positive donors14. A decreased 
incidence of  Transfusion associated-CMV infection 
was reported when only blood products negative for 
CMV IgM were used15. Most patients with AIDS who 
develop clinical signs and symptoms of  CMV infection 
probably have reactivation of  previous infection rath-
er than primary infection12-13. The prevalence of  HIV/
AIDS in Sub Saharan Africa is high but the description 
of  CMV infection as opportunistic infection amongst 
patients is scanty13.
The aims of  this study were to determine the preva-
lence of  CMV infection in HIV positive patients with 
and without past history of  blood transfusion and com-
pare our findings with those of  other studies. The study 
reports that 11.1% of  the HIV-1 seropositive patients 
tested were anti-CMV IgM seropositive and 93.9% were 
positive for anti-CMV IgG antibody.
This finding is in consonance with what has been pre-
viously reported. Akinsola et al.16 reported few cases of  
CMV retinitis in HIV infected Nigerians. The HIV pa-
tients who developed symptomatic CMV infection may 
have had the infection for a long time; immunosupres-
sion by HIV makes the virus to become pathogenic13. 
The higher the prevalence of  CMV in the general pop-
ulation, the higher should be the prevalence of  CMV 
infection in the population of  HIV infected patients13.
The 93.9% reported for anti-CMV IgG antibody sero-
positivity in this study is comparable to the values re-
ported in previous studies in Nigeria and outside. The 
seroprevalence of  CMV IgG of  96.0% was reported 
by Akinbami et al.1 in Lagos, Nigeria. Okwori et al.17 
reported a seroprevalence of  84.2% among pregnant 
women. Similar seroprevalence rates of  90.0 – 100.0% 
were also found in India18-20. The high seroprevalence in 
Nigeria and India contrasts with Western literature, in 
which seroprevalence ranges from 38.0% to 75.0%. A 
seroprevalence of  40.0% was found in highly industri-
alized nations8. Uyar et al.21 reported a 97.3% and 1.0% 
seropositivity for anti-CMV IgG and anti-CMV IgM 
antibodies respectively in Northern Turkey.
The seroprevalence of  CMV IgG of  100.0% among 
healthy blood donors was also found in the study of  
Krech8 done at Ibadan, Nigeria in 1973. A high sero-
prevalence of  between 90 -100% was also found in 
India amongst immunocompetent subjects in various 
studies13. Atul and Ramanchandrum20 found 95.0% se-
roprevalence of  CMV IgG amongst blood donors. A 
study by Pal et al.18 in 1972 showed 100.0% seropositiv-
ity for CMV IgG in a population of  immunocompetent 
adults. Madhavan et al.19 in 1974 showed that 84-96% 
of  immunocompetent adults had the antibody.
The  study  showed  that  the  seropositivity  of   an-
ti-CMV  IgG  and  anti-CMV  IgM  antibodies  were 
age dependent. The positivity for anti-CMV IgG and 
anti-CMV IgM antibodies was not found to be the same 
in all age groups. The age-related distribution of  an-
ti-CMV–specific IgM antibodies among the HIV-1 se-
ropositive subjects showed a significant difference in 
the levels of  anti-CMV IgG and anti-CMV IgM anti-
bodies among the various age groups tested (p=0.000). 
This is also in keeping with the findings of  previous 
studies. CMV infections occurs worldwide, about four 
out of  five people over age 35 have been infected with 
cytomegalovirus, usually during childhood or adult-
hood22. In most of  these people, the disease is so mild 
that it is overlooked23.
In line with a study by Dollard24, seroprevalence was 
also found to be age-dependent. Dollard24 reported 
58.7% of  individuals aged 80 and older were posi-
tive to CMV. Pal et al.18 in Chandigarh, India, showed 
100.0% seropositivity for CMV in the population aged 
>20 years, while Madhavan et al.19 in Pondicherry 
showed that 84.0 – 96.0% of  adults had the antibody. 
According to Abu-Madi et al.25, most of  the  children 
and  adolescents  in  Qatar,  Arabian  Gulf,  appear  to 
have  been  exposed  to  CMV with seroprevalences of  
79.0% in the 2 to 10-year and 91.0% in the 11 to 20-
year age groups25. Kassim et al.26 reported that 91.0% 
of  33 mothers were seropositive for CMV compared to 
33.0% of  their infants17.
Our study showed that the prevalence of  anti-CMV 
IgG and IgM antibodies was not sex dependent. The 
seropositivity for anti-CMV IgG and IgM antibodies 
was found to be the same in both males and females. 
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Single                  59(32.8)             5 (8.5)                                                 51 (86.4) 
 Multiple                 121(67.2)             15 (12.4)                             P<0.05                118 (97.5)                      P<0.05   
On HAART 
Yes                      20(11.1)             9 (45.0)                                               18 (90.0) 
 No                        160(88.9)             11 (54.4)                       P>0.05               151 (94.4)                        P>0.05   
Blood Transfusion 
Yes                      40(22.2)             6(15.0)                                                38(90.0) 
 No                        140(77.8)              14(10.0)                       P<0.05                131(93.6)                       P<0.05   
CD4 count (Cells/mm3) 
<50                     24(16.5)             2(8.3)                                                  21(87.5) 
51-100                 59(34.5)             8(13.6)                                                54(91.5) 
101-150               41(21.0)             4(9.8)                                                  39(95.1) 
151-200               16(8.0)               1(6.3)                                                  15(93.7) 
201-250               8(4.0)                1(12.5)                                                8(100.0) 
251-300               16(8.0)               3(18.8)                                                16(100.0) 
 >300                       16(8.0)                     1(6.3)                                  P<0.05                 16(100.0)                  P<0.05   
Total                  180(100.0)         20(11.1)                                              169(93.9) 
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Though, there was no significant difference (p=0.591) 
in the level of  anti-CMV IgG and IgM antibodies 
among the subjects, sex-related distribution of  CMV 
IgM among the HIV-1 seropositive subjects showed 
that of  the 108 females tested, 10(9.3%) were anti-CMV 
IgM positive and 10(13.9%) of  the 72 males tested were 
CMV IgM positive. Also from Table 1, it can be ob-
served that of  the 108 females tested, 100 (92.6%) were 
anti-CMV IgG positive and 69 (95.8%) males were pos-
itive for anti-CMV IgG. Existing evidence suggests that 
the concentrations of  IgG immunoglobulin in maternal 
and cord sera are essentially the same27.
In this study, a seroprevalence of  92.6% for CMV IgG 
and 9.3% for CMV IgM was observed in females. This 
is a deviation from what was reported by earlier workers 
in Nigeria and outside Nigeria17,27-30. In Brazil, 94.7% 
prevalence rate was reported among females30. In Gam-
bia, 14.0% of  178 Gambian babies were congenitally 
infected despite the fact that 87.0% of  their mothers 
were antibody positive to CMV28. At the time  of   de-
livery  of   96.0%  of   the  150  Egyptian  mothers  and 
their  newborn  infants  were  CMV-IgG seropositive29. 
This  study  has  shown  that  those  females  with  CMV 
IgG  antibodies  can  efficiently transferred the anti-
bodies to their developing foetus, if  pregnant. This may 
be due to the fact that IgG antibody is unique among 
the major immunoglobulin classes for its active transfer 
across maternal placenta25,31.
Transmission of  CMV is sexual24. Among the 59 
(32.8%) HIV-1 seropositive individuals with single sex-
ual partners, 5(8.5%) were anti-CMV IgM seropositive 
and 51(86.4%) were anti-CMV IgG seropositive. Of  the
121(67.2%)  HIV1-seropositive  individuals  with  mul-
tiple  sexual  partners,  15(12.4%)  were  CMV  IgM
seropositive  and  118(97.5%)  were  anti-CMV  IgG 
seropositive.  The  study  statistical  association  in  the 
seropositivity outcome of  anti-CMV IgM and anti-CMV 
IgG antibodies and the number of  sexual partners.
This study also determines the immune status of  HIV-
1 seropositive patients to CMV in Ilorin. In the stud-
ied population, 88.9% of  the HIV seropositive patients 
and 97.4% of  the HIV negative controls were immune 
to CMV. The implication of  these findings is that indi-
viduals seronegative for CMV are susceptible to CMV 
primary infections21. The CD4 cell counts-related distri-
bution of  CMV IgM and IgG antibodies among the re-
cruited HIV sero-positive subjects showed a significant 
association (X2= 1.155, p-value=0.0000) between CD4 
cells count and CMV IgM seropositivity. It showed that 
their CD4 cell counts ranged from 17 - 321 cells/mm3. 
Majority, 69(34.5%) had  CD4 cell  counts which ranged 
from 201-250  cells/mm3   while  the minority had CD4 
counts which ranged from 201-250 cells/mm3. From 
Table 2, it can be seen that majority, 8 (13.6 %) out of  
the 20 CMV IgM sero-positive individuals had CD4 cell 
counts which ranged from 51-100 cells/mm3 while 2 
(8.3%) had CD4 cell counts of  < 50 cells/mm3.
The distribution of  anti-CMV IgM and anti-CMV IgG 
in relation to marital status showed statistical associa-
tion (X2 = 1.306, p-value=0.002) in the anti-CMV sero-
positivity among the various marital groups. From the 
result, it can be deduced that 14(11.0%) of  the married 
subjects were anti-CMV IgM positive and 118(92.9%) 
were anti-CMV IgG positive, compared with the 12.8% 
seropositivity observed among singles and 7.1% among 
others (widows/widowers/divorced). Also, 118(92.9%) 
of  the married were anti-CMV IgG positive and com-
pared to 97.4% seropositivity among singles and 92.7% 
among others.
In term of  their HAART status, it can be seen that nine 
(45.0%) out of  the 20 that were CMV IgM positive 
were already on HAART, while 87(54.4%) out of  the 
160 that were not yet on HAART were also found to 
be CMV IgM sero-positive. There was no significant 
difference (X2= 0.080, p-value=0.777) in the level of  
CMV IgM among the HIV-1 sero-positive individuals 
tha t were on HAART and those that were not.
CMV-specific antibody of  the IgM class is a marker of  
active or recent primary infection with the virus. Trans-
mission of  CMV is also congenital (in birth), through 
blood product or transplantation, and person to person 
(e.g. day care centres)24. CMV infection constitute a real 
risk of  pathogenicity in immunocompromised patient, 
it is likely that HIV infected patients who develop CMV 
infection may have a previous history of  blood transfu-
sion13. Also HIV infected patients who require transfu-
sion are at high risk of  developing symptomatic CMV 
infection when they are transfused with CMV infected 
donor blood13. However, our present study showed no 
significant difference (X2= 1.412, p-value=0.837) in the 
level of  CMV IgM among those with history of  blood 
transfusion and those with no such history.
The results showed that of  the 40 (22.2%) subjects 
with previous history of  blood transfusion; 6(15.0%) 
were seropositive for anti-CMV IgM and 38(90.0%) 
for anti-CMV IgG antibody. While among those with 
no history, 14(10.0%) were positive for anti-CMV IgM 
and 131(93.6%) for anti-CMV IgG antibody. This is at 
variance with the work of  Tolpin and Stewart32 in 1985 
that provided the first biochemical and molecular evi-
dence for transfusion associated–CMV infection. Like-
lihood of  transfusion in HIV infected patient is found 
to be at least three times higher when compared with 
transfusion in all other patients in the medical wards  33. 
Thus,  predisposing  them  further  to  the  risk  of   ac-
quiring  CMV  infection  through  blood transfusion13. 
Although, some authorities are of  the opinion that the 
assertion claiming the individuals with IgM anti-CMV 
are more likely to transmit the virus than those with 
IgG anti-CMV is not proven beyond doubts15. Lamber-
son et al.15 found that a decreased incidence of  transfu-
sion-associated –CMV (TA- CMV) infection occurred 
when only blood products negative for CMV IgM were 
used.
Furthermore, the seropositivity of  CMV varies widely 
in the world. A number of  studies reveal a CMV se-
roprevalence of  56.3% in Finnish pregnant women34,21, 
78.0% in Russian pregnant women21,35 87.5% in preg-
nant women from Singapore36,21 and 92.1% in pregnant 
women from Saudi Arabia37,21. Gratacap-Cavallier et 
al. 38 found that CMV seroprevalence was significant-
ly higher in women born in southern France (51.6%) 
than in those born in northern France (37.4%)21. The 
prevalences of  anti-CMV IgG antibody reported in this 
study was also found similar to that of  other studies re-
ported in Turkey and other developing countries. CMV 
seroprevalence was reported to be 84.3% from Afyon, 
Turkey21,39, 92.6% from Ankara, Turkey40,21, 92.6% from 
Aydin, Turkey41,21, 94.9% from Antalya, Turkey21,42 and 
97.3 % from Hatay, Turkey43,21.
The detection of  virus-specific IgG and IgM antibodies 
is of  great value in the diagnosis of  acute/primary virus 
infections or reactivation of  a latent one, in the absence 
of  typical clinical symptoms. Asymptomatic infections 
usually happen for CMV in apparently healthy individu-
als, during pregnancy and several diseases as a coinfec-
tive agent. The high CMV seroprevalence found in this 
study underscores the importance of  using strategies to 
provide “CMV safe” blood to Haematologic Disorder 
Patients (HDPs) who are at high risk of  developing se-
vere CMV infection3.
Conclusion
This study has shown that greater percentages of  HIV-
1 seropositive patients had active CMV infection. It has 
further shown that CMV is hyperendemic in HIV-1 
seropositive patients in Ilorin, Nigeria. Unfortunately, 
vaccines for CMV have not yet been developed44. Pre-
ventive measures must be taken to decrease the mor-
tality and morbidity related to CMV infections21. There 
is therefore need to routinely screen blood donors and 
pregnant women for evidence of  CMV infection during 
their transfusion and antenatal visits respectively.
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